Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Cynosure Appoints Stephen J. Webber To CFO & Other Roles

Published 09/13/2016, 10:30 PM
Updated 07/09/2023, 06:31 AM

Marketer of aesthetic treatment systems, Cynosure, Inc. (NASDAQ:CYNO) announced that it has appointed Stephen J. Webber as Executive Vice President. The appointment will be effective from Oct 10, 2016. Webber would also take additional responsibilities of Chief Financial Officer and Chief Accounting Officer. However, the additional responsibilities would be effective upon the filing of Cynosure's quarterly report in November for the three-month period ending Sep 30, 2016.

Webber would succeed Timothy W. Baker, who announced his planned retirement from Cynosure in May to pursue philanthropic interests. However, Baker would continue to serve in a consulting role during a transition period expected to continue till Mar 2017.

Webber has a solid track record of operational and cost improvement, value creation and asset optimization. From 2012 to 2015, Webber was Senior Vice President of Finance and Operations at Dell EMC (NYSE:EMC) . Before that, he spent four years at Deloitte & Touche LLP in Boston in the audit practice with a focus on public companies.

Cynosure develops, manufactures, and markets aesthetic treatment systems. The systems aid plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures. The company also markets radiofrequency energy-sourced medical devices for precision surgical applications.

The company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the U.S., Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

Zacks Rank and Key Picks

Currently, Cynosure has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector include GW Pharmaceuticals plc (NASDAQ:GWPH) and Quidel Corp. (NASDAQ:QDEL) . Both stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



CYNOSURE INC-A (CYNO): Free Stock Analysis Report

GW PHARMA-ADR (GWPH): Free Stock Analysis Report

QUIDEL CORP (QDEL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.